argenex (ARGX) News Today

argenex SE (NASDAQ: ARGX) stock is trading higher, driven by strong financial results, multiple analyst price-target increases, and robust product sales, while an investor investigation adds some caution.

• Positive Sentiment: argenex beat Q2 estimates with EPS of $3.74 vs. $2.84 and revenue of $866.8 M vs. $776.8 M, boosting investor confidence in the company’s profitability. Q2 Earnings Press Release
• Positive Sentiment: Half-year 2025 results reported $949 M in global product net sales, progress in the VYVGART CIDP launch with over 2,500 patients, and advancement of ARGX-119 toward a registrational study. Half-Year Results Release
• Positive Sentiment: Guggenheim raised its price target to $1,070 with a Buy rating, implying a 58.8% upside. Guggenheim Price Target Raise
• Positive Sentiment: HC Wainwright lifted its target to $774 with a Buy rating, representing a 14.9% potential gain. HC Wainwright Price Target Raise
• Positive Sentiment: Morgan Stanley increased its target to $766 and maintained an Overweight rating, suggesting a 13.7% upside. Morgan Stanley Price Target Raise
• Positive Sentiment: Wells Fargo & Company raised its target to $756 with an Overweight rating, indicating a 12.2% upside. Wells Fargo Price Target Raise
• Positive Sentiment: ARGX shares reached a new 12-month high on renewed optimism around global product sales. MarketBeat New High Article
• Neutral Sentiment: Some media coverage addresses whether to maintain confidence in argenx given its rapid gains, without new material developments. MSN Confidence Article
• Negative Sentiment: Pomerantz Law Firm launched an investor investigation into argenx, introducing potential legal risk and uncertainty. Pomerantz Investigation Alert